Investigations into the pathogenesis of type 1 diabetes (T1D) implicate antigen interaction and co-stimulation as key pathways in disease development. A non-synonymous polymorphism in CD226 (rs763361), that encodes for a co-stimulatory molecule, has been linked to risk for T1D. The CD226 activating pathway is constrained by TIGIT, the high-affinity co-inhibitory receptor T cell immunoreceptor with Ig and ITIM domains, which competes with CD226 for ligands CD112/CD155. We have previously demonstrated that CD226 facilitates CD4+ T effector function, whereas TIGIT potentiates regulatory T (Treg) cell activity. Here, we report that both receptors impact CD8+ T cell pathogenesis. Both CD226 and TIGIT are upregulated upon human CD8+ T cell activation and are divergently expressed by memory CD8+ T cell subsets. These results support our finding in the positive correlation between age and CD226 or TIGIT expression (P=0.0002 and P<0.0001, respectively). Interestingly, TIGIT is co-expressed with the transcription factors T-bet and EOMES, whereas ∼80% of cytokine producing cells express CD226, demonstrating the coordinated expression of these factors with differentiated T cell lineages. We next sorted CD8+ T cells based on CD226 and TIGIT expression and assessed effector activity as well as gene expression profile following in vitro activation. Using a multiplex assay, we showed that CD226+ cells produced cytokines, chemokines, and cytolytic proteins (e.g., IFNγ, MIP-1α, granzyme B, and perforin) in a manner independent of TIGIT. Importantly, CD8+ T cell cytotoxicity to human β-cell line βLox5 that express high levels of ligands CD112 and CD155 is attenuated by blocking CD226 and enhanced by hindering TIGIT through a granzyme B dependent mechanism. These data support this co-stimulatory axis as a potential therapeutic pathway in T1D that could either attenuate CD226 co-stimulation of effector T cells, or inversely support tolerance induction by TIGIT signaling on Tregs.


W. Yeh: None. H. Seay: None. C.E. Mathews: None. T.M. Brusko: Stock/Shareholder; Self; OneVax, LLC. Advisory Panel; Self; Caladrius Biosciences, Inc.. Consultant; Self; Merck & Co., Inc., Sanofi-Aventis.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at